Korean Tobacco Reports Increase in Q2 Earnings

Aug.31.2022
Korean Tobacco Reports Increase in Q2 Earnings
KT&G's Q2 revenue rose 10.9%, boosted by overseas sales growth and higher real estate profits. Traditional cigarette sales also increased.

The latest financial report released by Korean Tobacco shows that their Q2 2022 revenue was KRW 1.42 trillion (approximately RMB 0.0052 per Korean won), a growth of 10.9% compared to the same period last year. The comprehensive operating profit was KRW 327.6 billion, an increase of 1% compared to the same period last year. Net profit reached KRW 330.1 billion, a year-on-year increase of 34%.


The company reported an increase in overall revenue, attributed to growth in overseas market sales and an improvement in real estate profit margins. The company's traditional cigarette business saw growth, benefiting from emerging markets such as South America and improved sales in Indonesia. Additionally, the company's heated tobacco product increased its market share in the domestic market from 40.4% in 2021 to 47% in 2022.


Currently, heated tobacco products account for 16.7% of all tobacco sales in South Korea. The company predicts that despite rising interest rates and soaring commodity prices, their traditional cigarette and electronic cigarette businesses will continue to grow in the coming months.


Statement


This article is compiled from third-party information and is intended for industry-related communication and learning purposes.


This article does not represent the views of 2FIRSTS and we are unable to confirm the authenticity and accuracy of its contents. The translation of this article is solely intended for industry communication and research purposes.


Due to limitations in translation abilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and positions.


The copyright for compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group releases 2025 results: tariffs and weaker demand weigh on performance, revenue about $1.4 billion
Scandinavian Tobacco Group (STG) reported its 2025 results: revenue was 9.036 billion Danish kroner (about $1.407 billion); EBITDA before special items was 1.791 billion Danish kroner (about $278 million); and free cash flow before acquisitions was 595 million Danish kroner (about $92.7 million). Multiple metrics declined year over year, and the company did not meet its Q3-updated guidance for revenue and free cash flow.
Mar.05 by 2FIRSTS.ai
Haypp Voluntarily Sets a 20 mg Nicotine-Strength Cap for Nicotine Pouches and Urges the UK to Establish a Regulatory Limit
Haypp Voluntarily Sets a 20 mg Nicotine-Strength Cap for Nicotine Pouches and Urges the UK to Establish a Regulatory Limit
Online nicotine pouch retailer Haypp said it has voluntarily adopted a 20 mg per pouch nicotine-strength cap across its e-commerce platforms and is urging the UK government to formalize that cap as the limit as it develops a regulatory framework. Haypp said proportionate limits would protect consumers while preserving nicotine pouches as a viable reduced-risk alternative to cigarettes.
Feb.26 by 2FIRSTS.ai
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
The West Virginia Senate approved a 10% personal income tax cut on February 22, 2026, with part of the revenue offset coming from increased excise taxes on vape and e-cigarette products.
News
Feb.23
European survey: current e-cigarette use among 15–19-year-olds rises from 14% (2019) to 22% (2024)
European survey: current e-cigarette use among 15–19-year-olds rises from 14% (2019) to 22% (2024)
A European study cited in the report says the share of young people aged 15 to 19 who are current e-cigarette users increased from 14% in 2019 to 22% in 2024, with Italy reflecting the broader European pattern. Over the same period, conventional cigarette smoking among young people is described as declining, with the proportion of students who have smoked at least once in their lifetime falling sharply from 1995 to 2024, and the largest drop occurring between 2019 and 2024.
Feb.12 by 2FIRSTS.ai
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA Outlines Manufacturing Requirements as Critical to ENDS PMTA Success
FDA officials said manufacturing consistency is a core prerequisite for ENDS PMTA reviews, not a procedural formality. During its February 10, 2026 roundtable, the agency outlined expectations for quality management systems, manufacturing documentation, nicotine control, stability studies, and risk mitigation, emphasizing that robust manufacturing evidence underpins determinations of whether products are appropriate for the protection of public health.
Feb.11